These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)]. Nagatsu T Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927 [No Abstract] [Full Text] [Related]
3. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea. McGeer PL; McGeer EG J Neurochem; 1976 Jan; 26(1):65-76. PubMed ID: 3629 [No Abstract] [Full Text] [Related]
8. Therapeutic efficacy of tetrahydrobiopterin in Parkinson's disease. Curtius HC; Niederwieser A; Levine R; Müldner H Adv Neurol; 1984; 40():463-6. PubMed ID: 6695623 [No Abstract] [Full Text] [Related]
9. Recent advances in research on Parkinsonism. Rinne UK Acta Neurol Scand Suppl; 1978; 67():77-113. PubMed ID: 31053 [No Abstract] [Full Text] [Related]
10. The "on-off" effect. Carlsson A Adv Neurol; 1974; 5():367-8. PubMed ID: 4155235 [No Abstract] [Full Text] [Related]
11. [Current perspectives in the treatment of Parkinson disease]. Rodríguez M; Palarea MD; Castro R; Pérez J; Arévalo R Med Clin (Barc); 1985 Nov; 85(15):633-40. PubMed ID: 2867259 [No Abstract] [Full Text] [Related]
12. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. Cohen G J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651 [TBL] [Abstract][Full Text] [Related]
13. Biochemical changes in normal aging in human brain. Côté LJ; Kremzner LT Adv Neurol; 1983; 38():19-30. PubMed ID: 6137133 [No Abstract] [Full Text] [Related]
14. Biochemical aspects of Parkinson's disease. Nagatsu T Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575 [No Abstract] [Full Text] [Related]
15. Biosynthesis and metabolism of the catecholamines. Sandler M Schweiz Med Wochenschr; 1970 Mar; 100(12):526-31. PubMed ID: 4906882 [No Abstract] [Full Text] [Related]
17. Mesangial cells are able to produce catecholamines in vitro. Di Marco GS; Naffah-Mazzacoratti Md Mda G; Vio CP; Dos Santos OF; Schor N; Casarini DE J Cell Biochem; 2003 May; 89(1):144-51. PubMed ID: 12682915 [TBL] [Abstract][Full Text] [Related]
18. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations]. Morselli PL; Rizzo M; Tognoni G Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589 [No Abstract] [Full Text] [Related]
19. What has been learnt from study of dopamine receptors in Parkinson's disease? Hurley MJ; Jenner P Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973 [TBL] [Abstract][Full Text] [Related]
20. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Danielsen EH; Smith D; Hermansen F; Gjedde A; Cumming P Synapse; 2001 Aug; 41(2):172-5. PubMed ID: 11400183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]